Rajeev M. Shah's Net Worth
$122 Thousand
Who is Rajeev M. Shah?
Rajeev M. Shah does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include AN2 Therapeutics, Inc., RHYTHM PHARMACEUTICALS, INC., Vaxcyte, Inc., iTeos Therapeutics, Inc., Mineralys Therapeutics, Inc., Cytek Biosciences, Inc., PMV Pharmaceuticals, Inc., Nkarta, Inc., DICE Therapeutics, Inc., Icosavax, Inc., Tyra Biosciences, Inc., MIRAGEN THERAPEUTICS, INC., Inhibrx, Inc., RxSight, Inc., Phathom Pharmaceuticals, Inc., Dyne Therapeutics, Inc., TG THERAPEUTICS, INC., Eliem Therapeutics, Inc., KalVista Pharmaceuticals, Inc., Vor Biopharma Inc., Verastem, Inc., Janux Therapeutics, Inc., Aerovate Therapeutics, Inc., Forma Therapeutics Holdings, Inc.,, Therapeutics Acquisition Corp., Synthorx, Inc., Eidos Therapeutics, Inc., Acumen Pharmaceuticals, Inc., 89bio, Inc., Solid Biosciences Inc., Inozyme Pharma, Inc., Pandion Therapeutics Holdco LLC, Iterum Therapeutics plc, Kala Pharmaceuticals, Inc., Orchard Therapeutics plc, Satsuma Pharmaceuticals, Inc., Akouos, Inc., Black Diamond Therapeutics, Inc., Cardiff Oncology, Inc., Werewolf Therapeutics, Inc., IMARA Inc., Ra Pharmaceuticals, Inc., Wave Life Sciences Ltd., Fulcrum Therapeutics, Inc., scPharmaceuticals Inc., ARS Pharmaceuticals, Inc., PepGen Inc., Acrivon Therapeutics, Inc., LENZ Therapeutics, Inc., Boundless Bio, Inc., Cidara Therapeutics, Inc., and Artiva Biotherapeutics, Inc..
SEC CIK
Rajeev M. Shah's CIK is 0001619841
Past Insider Trading and Trends
2018 was Rajeev M. Shah's most active year for acquiring shares with 5 total transactions. Rajeev M. Shah's most active month to acquire stocks was the month of May. 2020 was Rajeev M. Shah's most active year for disposing of shares, totalling 3 transactions. Rajeev M. Shah's most active month to dispose stocks was the month of March. 2021 saw Rajeev M. Shah paying a total of $10,636.43 for 65,443 shares, this is the most they've acquired in one year. In 2021 Rajeev M. Shah cashed out on 443 shares for a total of $10,636.43, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
AN2 Therapeutics, Inc. (ANTX) Snapshot price: $1.04
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| -63.50% | -3.53M |
$1.08 | -$3,807,101.52 | 2.03M |
Aug 9
| |||
Form 4
| +52.94% | 1.78M |
$9.00 | $16,000,002.00 | 5.14M |
Aug 18
| |||
Form 4
| +0.03% | 1.91K |
$7.74 | $14,330.32 | 7.55M |
Aug 3 - Aug 4
| |||
Form 4
| +0.62% | 23.22K |
$7.78 | $180,674.69 | 3.77M |
Jul 26 - Jul 27
| |||
Form 4
| +0.01% | 302 |
$7.99 | $2,412.98 | 3.75M |
Jun 21
| |||
Form 4
| +2.22% | 81.42K |
$7.95 | $647,401.86 | 3.75M |
Jun 13 - Jun 14
| |||
Form 4
|
∞
| 3.67M |
$15.00 |
—
| 3.67M |
Mar 29
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
RHYTHM PHARMACEUTICALS, INC. (RYTM) Snapshot price: $49.25
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| -5.19% | -238.54K |
$29.47 | -$7,029,652.62 | 4.36M |
Dec 2 - Dec 3
| |||
Form 4
| -2.50% | -131.58K |
$22.06 | -$2,902,517.12 | 5.14M |
Jun 30 - Jul 2
| |||
Form 4
| -2.77% | -150.32K |
$23.05 | -$3,465,614.60 | 5.27M |
Jun 25 - Jun 29
| |||
No matching records found |
Vaxcyte, Inc. (PCVX) Snapshot price: $111.58
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| -5.05% | -266.26K |
$50.78 | -$13,521,592.46 | 5M |
Oct 7 - Oct 8
| |||
Form 4
| -3.94% | -221.33K |
$49.81 | -$11,245,562.88 | 5.39M |
Sep 29 - Oct 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
iTeos Therapeutics, Inc. (ITOS) Snapshot price: $14.8
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| -26.12% | -900.00K |
—
|
—
| 2.55M |
May 10 - May 12
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 9
| |||
Form 4
| +13.93% | 421.21K |
$34.18 | $14,396,855.26 | 3.45M |
Apr 1
| |||
Form 4
|
∞
| 4.42M |
$19.00 |
—
| 4.42M |
Jul 28
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Mineralys Therapeutics, Inc. (MLYS) Snapshot price: $11.23
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 22
| |||
Form 4
| +127.55% | 1.67M |
$13.50 | $22,578,858.00 | 2.98M |
Feb 12
| |||
Form 4
|
∞
| 3.18M |
$16.00 |
—
| 3.18M |
Feb 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 9
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |